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The complement system is a component of the immune system involved in both recognition and response to pathogens, and it is implicated in an increasing number of
homeostatic and disease processes. It is well documented that reperfusion of ischemic
tissue results in complement activation and an inflammatory response that causes
post-reperfusion injury. This occurs following cerebral ischemia and reperfusion and triggers secondary damage that extends beyond the initial infarcted area, an outcome that
has rationalized the use of complement inhibitors as candidate therapeutics after stroke.
In the central nervous system, however, recent studies have revealed that complement
also has essential roles in synaptic pruning, neurogenesis, and neuronal migration. In the
context of recovery after stroke, these apparent divergent functions of complement may
account for findings that the protective effect of complement inhibition in the acute phase
after stroke is not always maintained in the subacute and chronic phases. The development of effective stroke therapies based on modulation of the complement system
will require a detailed understanding of complement-dependent processes in both early
neurodegenerative events and delayed neuro-reparatory processes. Here, we review
the role of complement in normal brain physiology, the events initiating complement
activation after cerebral ischemia-reperfusion injury, and the contribution of complement
to both injury and recovery. We also discuss how the design of future experiments may
better characterize the dual role of complement in recovery after ischemic stroke.
Keywords: complement, stroke, innate immunity, neuroprotection, brain ischemia, reperfusion injury

Introduction
Following cerebral ischemia, most patients reperfuse at least part of the ischemic area (1), and the
restoration of blood flow initiates an inflammatory cascade that causes secondary neuronal injury
which can have a significant impact on functional recovery. Reperfusion can occur spontaneously,
or can be achieved by surgical or pharmacological means (2). Once reperfusion occurs, there is
an inflammatory reaction in which resident cells, neutrophils, macrophages, platelets, cytokines,
molecular oxygen, and complement play important roles, and which culminates in necrotic and
apoptotic cell death (3). The only approved pharmacological agent for the treatment of ischemic
stroke is recombinant tissue-type plasminogen activator (tPA), which promotes reperfusion by
enhancing the dissolution of blood clots. However, tPA must be administered with 3 h of symptom
onset, and since there is a risk of uncontrollable intracranial hemorrhage, physicians are often reluctant to use this drug, with the result that only about 5% of stroke patients are treated with tPA (4, 5).
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There is thus a significant need for new and effective approaches
to treat stroke, and reducing inflammation and secondary injury
in the area surrounding the ischemic core (i.e., the penumbra) is a
major therapeutic goal. Nevertheless, it is becoming increasingly
clear that inflammation also has homeostatic functions within
the brain, and post-ischemic inflammation is also associated with
neural protection and regeneration. Therefore, understanding
how inflammation is involved in the balance between neurodegenerative and neuroprotective mechanisms will be important
for the development of therapeutics that optimally promote longterm functional recovery after stroke. Here, we review the role
of complement in neuroinflammatory processes during brain
homeostasis and in the post-ischemic brain.
In the CNS, as in other organs and tissues, complement plays a
key role in the inflammatory reaction following ischemia and reperfusion. Disruption of the blood–brain barrier following ischemic
stroke allows access of complement proteins to the brain, although
proteins of the complement system can be locally produced by
the cells of the CNS (6–8). Complement is implicated in human
ischemic stroke by studies demonstrating complement activation
in patients. Complement activation and deposition in areas of
cerebral ischemia has also been shown in rodent models of focal
cerebral ischemia, together with the upregulation of various complement proteins within the CNS. Studies utilizing complement
inhibited mice or mice genetically deficient in various complement
proteins have further helped elucidate the role of complement
in the pathogenesis of ischemic stroke and functional recovery.
However, as with other inflammatory processes, more recent studies have also documented a role for complement in homeostatic
functions within the brain, and complement is also associated with
post-ischemic neural protection, repair, and regeneration.

The Complement System

FIGURE 1 | Basic outline of the principle pathways of complement
activation and complement effector molecules. The classical pathway is
triggered by the binding of C1q to antibody Fc regions, pentraxins or certain
cell surface determinants. The lectin pathway is triggered by Mannosebinding lectin (MBL) or ficolins which bind to carbohydrate patterns, including
those found on some IgM antibodies. Both pathways lead to cleavage of C2
and C4 components, forming the classical pathway C3 convertase (C4b2a)
that cleaves C3. The alternative pathway is spontaneously activated forming
the alternative pathway C3 convertase (C3bBb), and it also serves to amplify
classical and lectin pathway activation. Cleavage of C3 leads to the
generation of C3a and C3b. Activated C3b deposits on cell surfaces and is
further degraded to iC3b, C3dg, and C3d, which serve as opsonins for
receptors on immune cells. In addition, C3b associates with preformed C3
convertase, forming C5 convertase that in turn cleaves C5 into C5a and C5b.
Deposition of C5b on cell surface initiates assembly of the cytolytic
membrane attack complex (MAC or C5b-9). The C5a and C3a
anaphylatoxins are potent pro-inflammatory molecules, and also modulate
various homeostatic effects through G-protein signaling.

In addition to its well-documented role in host defense, complement plays important roles in various other physiologic and
homeostatic functions, such as immune complex catabolism, the
clearance of dead and dying cells, and the modulation of adaptive immune responses. Complement is also involved in various
developmental and regenerative processes, and is integrated with
multiple other biological systems and pathways [reviewed in Ref.
(9)]. Complement activation products consisting of opsonins,
anaphylatoxins, and a terminal cytolytic complex mediate the
effector functions of complement. The complement cascade is
activated by one of three pathways, referred to as the classical,
alternative, and lectin pathways, and all pathways converge at the
cleavage and activation of the complement protein C3 (Figure 1).
In general, the classical pathway is activated by antibodies and
apoptotic cells via recognition by C1q, and the lectin pathway is
activated via recognition of carbohydrate patterns by mannosebinding lectin (MBL) or ficolins. The alternative pathway is constitutively active, and spontaneously hydrolyzed C3 can become
deposited on any surface to take part in further C3 activation on
that surface. An alternative pathway-activating surface is one that
is unable to regulate further C3 activation and amplification. The
alternative pathway also functions to amplify the classical and
lectin pathways. There are, however, additional means by which
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complement can be activated. Extrinsic protease pathways can
bypass the early pathways of complement activation and directly
cleave C3 or C5 proteins; for example, thrombin can directly
cleave C3 and act as a C5 convertase (10, 11). The initial products
of C3 cleavage are soluble C3a and cell-bound C3b. C3b is further
cleaved to yield membrane-bound iC3b, C3dg, and C3d opsonins
that are recognized by receptors on immune cells. C3 cleavage also
leads to C5 cleavage to yield soluble C5a and membrane-bound
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C5b. C5b initiates the terminal pathway and formation of the
membrane attack complex (MAC) that can cause direct cell lysis,
but that can also stimulate cells to release inflammatory molecules.
The anaphylatoxins C3a and C5a have multiple physiologic and
inflammatory activities, including the recruitment and activation
leukocytes. Complement is regulated by various fluid-phase and
membrane-bound inhibitors [reviewed in Ref. (12)].

cleavage of Bid, increase in cellular FLIP long isoform, and downregulation of FasL expression (27, 28). The use of PI3K inhibitor
(LY294002) partly reversed the effects of MAC on oligodendrocyte survival, suggesting that sublytic MAC concentrations may
promote downstream signaling through the PI3K pathway (28).
On the other hand, it has been shown that complement receptor
2 (CR2) is expressed in adult neural progenitor cells of the dentate
gyrus, and that the CR2 ligands C3d and interferon-α inhibit
neural progenitor cell proliferation. Furthermore, CR2-deficient
mice displayed increased basal neurogenesis, indicating that CR2
may regulate neurogenesis and that complement activation (via
C3d generation) may inhibit neurogenesis (29).
The C3a and C5a anaphylatoxins signal through the C3aR and
C5aR1 G-protein coupled receptors, but we lack a clear understanding of their function and downstream effector mechanisms
in the CNS. Certainly both anaphylatoxins can promote the
production of cytokines and inflammatory mediators, and can
direct and activate leukocytes, but they can also affect neuronal
survival and synaptic plasticity. For example, C5aR1 is expressed
on pre-synaptic terminals of mossy fibers within the hippocampus, suggesting a possible role for this receptor in synaptic/
cellular plasticity (30). In addition, expression of C3aR on both
neurons and glial cells suggests that C3a may play a role beyond
immunological protection (31). Several studies have investigated
common and different neuroprotective mechanisms of C3a and
C5a. C3a was found to be involved in basal and ischemia-induced
neurogenesis that was inhibited in C3-deficient mice and in mice
treated with C3a receptor antagonist (C3aRA) (32). In murine
primary neuronal cultures, C3a reversibly bound to neuronal cells
promoting migration and differentiation through the recruitment
of the intracellular ERK1/2 signaling pathway (33). C5a also
recruited the ERK1/2 signaling pathway in response to glutamateinduced neurotoxicity (34). In this latter study, C5a was found
to inhibit DNA fragmentation and pro-caspase-3 activation in
neuronal and hippocampal cultures. Both C3a and C5a were
found to increase the gene expression of neuronal growth factor
in microglia, an effect mediated by C3aR and C5aR1 and inhibited
by pertussis toxin (that blocks G-protein (Gi) coupled receptors)
(35, 36). The increase in neuronal growth factor mRNA levels was
not always associated with significant protein upregulation, but a
significant synergistic effect of both anaphylatoxins with IL-1β on
neuronal growth factor protein upregulation has been reported
(36). Both C3a and C5a contributed to neuroprotection from
glutamate-induced excitotoxicity, although each peptide had a different specific protective pattern. C3a was only protective against
N-methyl-d-aspartate (NMDA) in the presence of astrocytes, and
did not contribute to neuroprotection against Kainaite-induced
excitotoxicity (37). By contrast, C5a exhibited a neuroprotective role in Kainaite rather than NMDA neurotoxicity. Also,
intraventricular infusion of both Kainic acid and C5a in mice
reduced caspase-3 activation and neuronal apoptosis (38), and
C5aR1-deficient mice were shown to have increased susceptibility
to Kainaite-induced excitotoxicity compared to wild type; treatment of wild-type mice with C5a reversed the glutamate-induced
decrease in GluR2 receptor and reduced neuronal apoptosis (39).
More recently, C5a was shown to reduce extracellular glutamate
accumulation through the upregulation of glutamate transporter

Complement in Brain Homeostasis
In contrast to systemic complement proteins that are produced
predominantly by the liver, complement proteins are also be synthesized locally in the CNS. Primary studies using astrocyte and
glial cell cultures demonstrated that these cells express nearly all
components of the complement system (6–8). It was also shown
that bacterial infection or inflammation increased expression of
complement mRNA in the CNS (13, 14). Early studies focused on
the protective role that the complement system played in the CNS,
including sensing and response to infection, and the clearance
of debris, apoptotic cells, and plaques (15–18). Further Research
has also uncovered an essential role for complement in key
aspects of brain function such as in synaptic pruning during CNS
development, as well as other forms of synaptic plasticity (19–21).
Evidence for the role of complement in elimination of synapses
came from studies on the development of the retinogeniculate
pathway in mice (19–21). C1q and C3 proteins produced by astrocytes were found to tag weaker synapses for removal by microglia,
which drives specific innervation. This process reduces excessive
connectivity between brain areas that may seed epileptogenesis as
reported in C1q−/− mice (22). In addition, the anaphylatoxins, C3a
and C5a, have also been implicated in cerebellar development in
neonatal rats. C3a and C5a receptors (C3aR and C5aR1) were
transiently elevated in rat cerebellar granule neurons peaking
on the 12th postnatal day (23), and agonists to these receptors
transiently altered the thickness of cerebellar cortical levels. A
C5a agonist caused enlargement of the external granule layer and
promoted granule cell survival by inhibiting caspase-9 activity and
maintaining mitochondrial integrity. A C3a agonist increased the
thickness of the internal granule layer while reducing the thickness of the external granule layer, suggesting a putative role of C3a
in accelerating the migration of granule cells from the external to
internal granule layer (23, 24).
Components of classical and terminal complement pathways,
along with the complement anaphylatoxins, have also been shown
to play a role in neurogenesis and neuroprotection. The addition
of C1q to rat primary neuronal cultures resulted in alteration
in microRNA and mRNA expression in a direction promoting
neuronal survival (25). Pathways implicated in this effect include
cholesterol metabolism, synaptic function, and neuronal growth
factor production. A similar neuroprotective role for C1q was
reported in response to β-amyloid and serum amyloid P-induced
neurotoxicity (26). Interestingly, the MAC also demonstrated a
pro-survival effect on oligodendrocyte progenitor cells at sublytic
concentrations. Different pathways were thought to mediate the
survival and proliferative effects of sublytic MAC on oligodendrocyte progenitor cells in vitro, including the inhibition of caspase-3
and caspase-8 activation, upregulation of bcl-2 expression,

Frontiers in Immunology | www.frontiersin.org

3

August 2015 | Volume 6 | Article 417

Alawieh et al.

Complement in homeostatic and ischemic brain

GLT-1 in microglia, suggesting a distinct mechanism of protection against excitotoxicity (40). Figure 2 summarizes the interplay
between the complement system and other immune components
in brain physiology and response to pathology.

(42, 43). In addition, blocking C5a signaling by the use of C5aR1
antagonist or the use of neurons from C5aR1-deficient mice
reduced ischemia-induced apoptosis in murine neuronal cultures
indicating a pathogenic role for C5a (44, 45). The neuroprotective
effect of C5aR1 antagonism could be enhanced with hypothermia
without alteration in C5aR1 levels, suggesting a putative therapeutic advantage of coupling both treatments (45). On the other hand,
human neurons were found to express the complement inhibitors
CD59, CD46 (membrane cofactor protein) and CD55 (decay
accelerating factor), and hypoxic insult neither altered inhibitor
expression nor the deposition of C3d, suggesting that human
neurons are protected from the effects of C3 opsonization and the
MAC (46). Table 1 shows a brief summary of the different in vitro
studies on complement involvement in experimental stroke.

Complement in Brain Ischemia and
Reperfusion Injury
The complement system has long been recognized as a potential
therapeutic target for the reduction of secondary damage and
improvement of outcome after stroke. Research has focused on
identifying the role of complement in brain ischemia-reperfusion
injury (IRI) and investigating how complement inhibition affects
outcome in models of stroke. There follows a summary of studies
that have been performed in vitro, in animal models of ischemic
and hemorrhagic stroke, and in human stroke.

In Vivo Studies

Animal models of ischemic stroke involve transient or permanent
occlusion of the middle cerebral artery or common carotid artery,
or cerebral clot embolization. Notably, the advantage of the cerebral embolization model, although more difficult and less commonly utilized, is that it better allows the evaluation of the effect
of potential adjuvant therapies to tissue plasminogen activator
(t-PA), the only approved treatment for acute stroke. As a plasma
protease, t-PA is capable of proteolytically activating components
of the complement system via the recently recognized extrinsic
pathway. In support of this, an early study reported that after
cerebral embolization rabbits treated with t-PA had higher levels
of C3 and C5 compared to vehicle (47). Interestingly, complement
depletion in the same model using cobra venom factor (CVF) did
not have any effect on infarct size in the presence or absence of t-PA
treatment (48). However, this study did not investigate other outcome measures that complete complement depletion may affect,

Insight from In Vitro Studies

Oxygen-glucose deprivation of cultured neuronal cells is a widely
used in vitro model for cerebral ischemia, a procedure that results
in both apoptotic and necrotic cell death. Upon hypoxic insult,
neuronal cultures have been shown to overexpress several complement proteins. Both mRNA and protein levels of C1q were elevated
in rat neuronal cells exposed to hypoxia, and newly produced C1q
preferentially deposited on hypoxic neurons, serving as both a
primary opsonin and an activator of the complement cascade (41).
Similarly, mouse and rat neuronal cell cultures showed increased
C3 expression in response to hypoxia, a response that was shown
to be associated with activation of caspase-3, a marker for apoptosis. Both C3 expression and caspase-3 activation were reduced
with intravenous immunoglobulin (IVIG) treatment, suggesting
that IVIG may represent an interventional therapy for stroke

FIGURE 2 | The interplay between complement system and other immune components in normal and pathological brain.

Frontiers in Immunology | www.frontiersin.org

4

August 2015 | Volume 6 | Article 417

Alawieh et al.

Complement in homeostatic and ischemic brain

TABLE 1 | Summary of in vitro studies on the role of complement in cerebral I/R.
Study

Disease

Cell type

Model

Treatment

Pathway

Findings

(43)

Ischemic
stroke

Mouse cortical
neuron culture

Oxygen-glucose
deprivation (3 h)

siRNA C3
inhibition

All pathways

(1) Inhibition of C3 expression reduced oxidative stress. (2) Ischemia
promotes an increase in C3 promoter activity

(44)

Ischemic
stroke

Mouse cortical
neuron culture

Oxygen-glucose
deprivation (12 h)

C5a C5aRA
(PMX53)

All pathways

(1) C5a caused neuronal apoptosis through C5aR. (2) PMX53 blocked
ischemia-induced apoptosis

(41)

Ischemic
stroke

Rat PC 12 cells

Hypoxic chamber
(9 h)

None

Classical
pathway

(1) C1q mRNA was not expressed in PC12 but started to be expressed
after hypoxia. (2) C1q protein antibody bound to the cells after hypoxia

(42)

Ischemic
stroke

Rat embryo
neuronal culture

Oxygen-glucose
deprivation (24 h)

IVIG

All pathways

(1) C3 levels increased in cultured neurons upon OGD with a parallel
increase in caspase-3. (2) IVIG reduced the levels of C3 and caspase-3
after OGD

(45)

Ischemic
stroke

Astrocyte mouse
culture

Oxygen-glucose
deprivation
(6–12 h)

C5aRA
C5aR−/−

All pathways

(1) C5aRA after OGD and C5aR−/− significantly reduced cell death and
cytoplasmic LDH release. (2) Neuroprotective effect of C5aRA was
enhanced upon hypothermia. (3) Expression of C5aR was not affected by
hypothermia

(46)

Ischemic
stroke

NT2-N human
neuronal culture

1 and 0.1%
hypoxia for 3 h

None

All pathways

(1) CD59 was strongly expressed on NT2-N neurons along with CD55,
CD46, C3aR, and C5aR. (2) Only CD55 was affected by hypoxia with a
reduction of expression. (3) Hypoxia exposure did not affect deposition
of C3d

and no subsequent studies have further investigated the crosstalk
between t-PA and the complement system in the context of acute
stroke treatment (Table 2). The use of CVF in rodent models of
transient ischemia consistently demonstrates a protective effect
of complement depletion. Rats subjected to bilateral transient
common carotid artery occlusion and pretreated with CVF had
a better outcome compared to control treated rats in terms of
somatosensory evoked potentials (49). CVF also reduced infarct
volume and neuronal atrophy after rat transient middle cerebral
artery occlusion (MCAO), as well as after neonatal rat hypoxia
(50, 51). However, in permanent ischemia rat model, CVF did
not effectively reduce infract volume (52). The prominent role of
reperfusion in the activation of plasma complement proteins near
ischemic tissue may explain why complement depletion did not
alter outcomes in models utilizing permanent ischemia.
Following stroke, damage to the blood–brain barrier will
allow access of hematogenous complement proteins to the CNS,
but there is evidence that increased local expression of complement proteins contribute to secondary injury after ischemia. For
example, expression of C1q, C3, and CD11b (a component of
complement receptor 3 expressed on phagocytes) is upregulated
in response to ischemia in models of transient MCAO (54, 58,
60, 81). Interestingly, the increase in C1q mRNA expression was
specific to microglia and did not occur in neurons or astrocytes
(54), but C1q protein in the ischemic brain co-localized with
the neuronal marker MAP2, suggesting that C1q is produced by
microglia in response to ischemia and accumulates on neuronal
cells (58). However, despite increased expression of C1q, the role
of the classical pathway in post-ischemic injury is not completely
clear since whereas C1q deficiency protects against murine neonatal hypoxic-ischemic brain injury (79, 85), it does not protect
against murine transient MCAO (60). In neurodegenerative diseases, C1q and or C3 opsonization of synapses stimulates microglial phagocytosis, and complement-mediated synaptic clearance
precedes neuronal loss (21, 86). During development, however,
C1q and C3 opsonins have been shown to play an essential role
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in synaptic pruning and neuron remodeling (21). A feature of
cerebral IRI is that it carries characteristics of both neurodegenerative disease and developmental mechanisms. Activation of
inflammatory cascades after stroke causes significant secondary
injury resulting in loss of both synapses and neurons in the
penumbra area. Following this early insult, stroke is characterized
by a window of neuroplastic response that mimics early developmental mechanisms including axonal growth and sprouting, and
formation of new synapses and intra-cortical projections (87–89)
[see reviews (90, 91)]. An important, yet unexplored question,
is whether inhibition of the complement system after cerebral
ischemia and reperfusion reduces loss of synaptic connections
in the ischemic penumbra or whether this inhibition will prevent
adequate synaptic pruning during rehabilitation induced cortical
re-organization.
In an influential paper on the application of complement inhibition in stroke, Huang et al. described the use of soluble complement
receptor 1 (sCR1) and its sialyl Lewis × glycosylated form (sCR1sLex) to study the effect of systemic complement inhibition and
selectin-targeted complement inhibition on outcomes after murine
stroke. Soluble CR1 inhibits all complement pathways at the C3
activation step, and the sLex carbohydrate moiety binds to both P
and E selectin, adhesion molecules that are upregulated on activated
endothelium. Following MCAO and reperfusion, sCR1 modestly
reduced ischemic injury while sCR1-sLex markedly diminished
infarct volume, improved neurological outcome, and inhibited
leukocyte migration (55). Thus, decoration sCR1 with the sLex
moiety increased the efficacy of complement inhibition by targeting the inhibitor to selectin-expressing activated brain endothelial
surfaces. A more recent study demonstrated that a truncated form
of sCR1 also significantly improved outcome in a rat model of transient MCAO (78). Nevertheless, studies in a non-human primate
stroke model failed to reproduce the earlier findings of sCR1 and
sCR1-sLex treatment that was reported in mice (59). Similarly, the
therapeutic value of sCR1-sLex failed to translate to baboons in a
study by Ducruet et al. (66). In this latter study, sCR1-sLex reduced
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TABLE 2 | Summary of studies investigating the role of complement in cerebral I/R using animal models.
Study

Disease

Species

Model

Treatment

Pathway

Findings

(53)

Hemorrhagic
stroke

Mouse

Intracerebral hemorrhage

C3−/−
C5−/−
WT + C5aRA (PMX53)
WT

All pathways

(1) C3−/− had less brain edema but more cognitive and neurological deficit compared to C5−/−. (2)
C5aR peaks at day 3 and is not expressed in sham. (3) C5aRA decreases C5aR expression and
improves functional outcome alone and in combination with anti-thrombin therapy up to 5 days
after surgery

(43)

Ischemic stroke

Mouse

Transient-MCAO (45 min
occlusion time)

SOD1Tga

All pathways

(1) SOD2KO had higher oxidative stress and increased brain C3 expression. (2) C3 expression
involved microglia and neurons. (3) C3 expression was reduced by PBN compared to vehicle, and
was reduced in SOD1Tg compared to WT up to 7 days after ischemia. (4) PBN reduced infarct
volume and improved outcome up to 7 days after ischemia

All pathways

(1) C5aR−/− were protected against ischemia compared to WT. (2) C5a increase post-ischemia in
WT specifically in neurons. (3) C5−/− had a reduced lesion volume and better neurological outcome
compared to WT 24 h after reperfusion

SOD2

−/−

WT
WT + PBNb
(44)

Ischemic stroke

Mouse

Transient- MCAO (1 h
occlusion time)

CD88−/− (C5aR)
C5

−/−

WT + C5a
Ischemic stroke

Rabbit

Cerebral embolization

WT + t-PA

All pathways

Both C5 and C3 were significantly more activated in t-PA-treated rabbits compared to vehicle

(48)

Ischemic stroke

Rabbit

Cerebral embolization

WT + CVF +/− t-PA

All pathways

Complement depletion did not have effect on infarct size up to 7 h after embolization in any of the
groups compared to controls

(54)

Ischemic stroke

Rat

Transient global cerebral
ischemia (15 min)

None

Classical
pathway

(1) Ischemia increased C1q mRNA expression and activity 24–72 h. (2) C1q was specifically
expressed in microglia not in neurons or astrocytes

(55)

Ischemic stroke

Mouse

Transient- MCAO (45 min
occlusion time)

WT + sCR1 (block C1q)

All pathways

(1) sCR1 modestly reduced acute (24 h) injury given just before ischemia. (2) sCR1-sLex markedly
diminished infarct volume in a dose-dependent fashion and improved neurological outcome more
than sCR1. (3) Ischemia had threefold increase in leukocyte migration that was inhibited by sCR1Lex and not sCR1. Measurements were performed 24 h after ischemia

6

(47)

c

WT + sCR1-sLex (block C1q
and selectin)

Ischemic stroke

Rat

Transient- MCAO (60 min
occlusion time)

WT + C1 inhibitor

Classical
pathway

Given reperfusion, C1 inhibitor reduced the infarct volume as well as myeloperoxidase activity 48 h
after reperfusion.

(57)

Ischemic stroke

Mouse

Transient- MCAO (60 min
occlusion time)

WT + CR2-Crry
(30 min-postR)

All pathways

(1) C3−/− and CR2-Crry-treated mice had improved survival, reduced infarct volume and expression
of P-selectin and improvement of neurological outcome at 24 h after reperfusion. (2) C3−/− had less
apoptotic neurons than sham and CR2-Crry

August 2015 | Volume 6 | Article 417

CD3−/−
(58)

Ischemic stroke

Mouse

Transient- MCAO (60 min
occlusion time)

None

Classical
pathway

(1) C1q begins to accumulate in the brain after 6 h of ischemia. (2) C1q colocalizes with MAP2 on
neurons during ischemia

(59)

Ischemic stroke

Baboons

Transient- MCAO (75 min
occlusion time)

WT + sCR1

All pathways

(1) C1q blockade by sCR1 did not affect infarct volume or neurological outcome up to days after
surgery. (2) C1q was deposited in the ischemic brain of vehicle-treated baboons and sCR1 was
detected in the other group at 72 h after ischemia
(Continued)

Complement in homeostatic and ischemic brain

(56)
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TABLE 2 | Continued
Species

Model

Treatment

Pathway

Findings

(60)

Ischemic stroke

Mouse

Transient- MCAO (60 min
occlusion time)

C1qa−/−
C3−/−
C5−/−
WT + C3aRA

Classical and
common
terminal
pathway

(1) C1q, C3, and C5 deposited in the ischemic side of WT but not contralaterally. (2) C1q−/− did
not experience improvement in cerebral infarct volumes, neurological outcome, or mortality
compared to WT. (3) C3−/− and C3aRA-treated WT had significant improvement in infarct volume
and neurological outcome with less granulocyte infiltration and no effect on mortality. (4) C3−/−
improvement was reversed in C3-treated C3−/− mice. (5) C5−/− did not have significant change in
infarct volume or mortality. Outcomes were assessed 24 h after ischemia

(49)

Ischemic stroke

Rat

Bilateral common carotid
artery occlusion (15 min)

WT + CVFc pretreatment

Non-specific

CVF improved neurological outcome as measured by somatosensory evoked potentials up to 4 h
after reperfusion

(61)

Neonatal
hypoxicischemic
encephalitis

Rat

Unilateral common carotid C9−/− + sCR1
ligation and hypoxic
C9−/− + sCR1-sLex
atmosphere exposure
C9−/− + CVFc
C9−/− + C9

Classical and
common
terminal
pathway

(1) sCR1, sCR1-sLex, or CVF did not affect the infarct volume in C9−/− neonatal rats. (2) C9
administration caused a significant increase in infarct volume in C9−/− compared to vehicle
measured after 24 h

(50)

Neonatal
hypoxicischemic
encephalitis

Rat

Unilateral common carotid WT + CVFc
ligation and hypoxic
atmosphere exposure

All pathways

(1) Hypoxia-induced iC3b and C9 accumulation in the brain after 16 and 24 h, respectively. (2)
C3 and C9 first localized to endothelium and then to neurons. (3) CVF given 24 h before ischemia
reduced infarct size without eliminating complement deposition mainly C9

(62)

Ischemic stroke

Mouse

Transient- MCAO 120 min WT + C1 Inhibitor
occlusion time

Classical
pathway

(1) C1 inhibitor given after ischemia reduced focal and general deficit as well as ischemic volume at
48 h after ischemia. (2) C1 inhibitor did not stop the increase in astrocyte activation

(52)

Ischemic stroke

Rat

Permanent MCAO

WT + CVFc
WT + CRP

All pathways

(1) CVF did not affect the infarct volume. (2) Infarct volume significantly increased after CRP
treatment

(63)

Ischemic stroke

Mouse

Transient- MCAO
(120 min occlusion time)

WT + C1 Inhibitor

Classical
pathway

(1) C1 inhibitor given at time of ischemia reduced general and focal deficits and reduced ICAM-1
and P-selectin expression. (2) C1 inhibitor also reduced pro-caspase-3 and neurofilament H
expression and affected cytokine levels

(64)

Ischemic stroke

Mouse

Transient- MCAO (30 min
occlusion time)

WT + C1 Inhibitor

Classical
pathway

(1) C1 inhibitor reduced infarct volume in a dose-dependent fashion only when given before
reperfusion. (2) C1 inhibitor also reduced general and focal deficits, neuronal apoptosis and
leukocyte infiltration up to 4 days. (3) C1q−/− had non-significant reduction in infarct volume, but
significant reduction in ischemic volume

C1q

−/−
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(65)

Ischemic stroke

Mouse

Transient- MCAO (60 min
occlusion time)

WT + C5aRAd

All pathways

C5aRA had significant reduction in infarct volume and improved neurological outcome 24 h after
ischemia

(66)

Ischemic stroke

Mouse

Transient- MCAO (60 min
occlusion time) and
permanent MCAO

WT + C3aRAe

All pathways

(1) C3aRA caused smaller infarct volume less upregulation of C3aR-positive granulocytes, and
less ICAM-1 protein on endothelial cells. (2) No significant change in infarct volume with C3aRA
treatment 24 h after reperfusion

(67)

Hemorrhagic
stroke

Mouse

Intracerebral hemorrhage

WT + C3aRA
WT + C5aRA
WT + C3aRA and C5aRA

All pathways

(1) All three groups had better performance in morris water maze compared to vehicle. (2) C5aRA
only and double treatment showed significant improvement on corner turn test, better neurological
score, and reduced granulocytes 72 h after surgery
(Continued)
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TABLE 2 | Continued
Disease

Species

Model

Treatment

Pathway

Findings

(51)

Ischemic stroke

Rat

Transient MCAO (30 min)
for adults and unilateral
carotid artery ligation
followed by hypoxia in
neonates

WT + CVFc pretreatment

All pathways

CVF reduced IV in adults and significantly preserved parenchymal volume in neonates and reduced
cerebral atrophy 2 days after surgery

(42)

Ischemic stroke

Mouse

Transient- MCAO (60 min
occlusion time) and
permanent MCAO

WT + IVIG
WT + C5aRA
C5−/−

Non-specific

(1) IVIG reduced mortality, infarct size, and functional impairment. (2) C5−/− mice had improved
outcome and less damage than controls, but C5aR Ant did not improve the outcome significantly.
(3) IVIG significantly reduced C3b levels compared to controls as well as levels of ICAM-1, CD11a,
and CD11b at 72 h post reperfusion

(68)

Ischemic stroke

Baboons

Cerebral artery clips
(75 min)

WT + sCR1-sLex

Classical
pathway

(1) sCR1-Lex significantly lowered CH-50 but had no significant effect on neurological outcome. (2)
sCR1-Lex-treated baboons had a larger infarct volume compared to controls

(69)

Hemorrhagic
stroke

Mouse

Intracerebral hemorrhage

WT + C3aRA

Non-specific

(1) C3aRA pretreatment caused less peri-hematomal edema but no change in hematoma size
and a gradual recovery of function not significant compared to vehicle. (2) C3aRA treatment post
reperfusion had no significant reduction in edema or improvement of outcome up to 72 h

(70)

Ischemic stroke

Mouse

Transient- MCAO (30 min
occlusion time) and
permanent MCAO

WT + recombinant C1
Inhibitor (Rh C1Inh)

Classical
pathway

(1) RhC1Inh but not pdC1Inh bound to MBL and was more effective inhibiting lectin pathway. (2)
C1Inh reduced infarct volume if given up to 18 h post transient ischemia or within 6 h of permanent
occlusion

8

Study

WT + plasma derived C1
Inhibitor (pdC1Inh)

Ischemic stroke

Mouse

Transient- MCAO (60 min
occlusion time)

C3−/−
C6−/−
C1q/MBL−/−
Factor B−/−
CD59−/−
WT + CR2-fHf
WT + CR2-Crryg

Classical and
alternative
pathway.

(1) Factor B−/−, C1q/MBL−/−, CR2-fH and CR2-Crry but not C6−/− improved neurological outcome
and reduced infarct volume. (2) CR2-fH was found also to reduce astrocyte reactivity and cellular
apoptosis. (3) Reduction of infarct volume with CR2-fH was also seen at 7 days post reperfusion.
(4) CD 59 deficiency did not affect injury after 60 min ischemia

(73)

Ischemic stroke

Mouse

Transient- MCAO (30 min
occlusion time)

WT + C3aRA

All pathways

Acute (45 min before ischemia and then daily) C3aRA treatment (1) increased neurogenesis in
a dose-dependent fashion on day 7, (2) reduced T-cell infiltration, (3) reduced infarct volume,
mortality and neurological deficit

(74)

Ischemic stroke

Mouse

Transient- MCAO (60 min
occlusion time)

MBL+/+
MBL−/−

Lectin
pathway

(1) 15 min post reperfusion, CD11b increased in both neutrophils of MBL+/+ and MBL−/− without
difference but significantly more than sham. (2) There was no significant difference in infarct
volume, brain edema, C3 and C1q deposition between MBL+/+ and MBL−/− groups at 24 h after
reperfusion

(75)

Ischemic stroke

Mouse

Permanent MCAO

Adrenomedullin (AM)−/−
Factor H−/−

Alternative
pathway

(1) Both AM−/− and Factor H−/− did not cause a significant change in infarct volume, endothelial
NOS, MMP9, and COX-2 at 2 days after ischemia. (2) Bechlin-1 significantly increased after injury
and together with iNOS was significantly higher in AM−/− compared to WTh
(Continued)

Complement in homeostatic and ischemic brain

August 2015 | Volume 6 | Article 417

(71,
72)

Alawieh et al.

Frontiers in Immunology | www.frontiersin.org

TABLE 2 | Continued

9

Study

Disease

Species

Model

Treatment

Pathway

Findings

(76)

Ischemic stroke

Mouse

Transient- MCAO (60 min
occlusion time)

CD59a−/−

All pathways

(1) CD59a−/− mice had more neurological impairment 30 min after MCAO and increased neuronal
apoptosis at 1 h. (2) CD59a deficiency did not affect number of CD11b positive cells

(77)

Ischemic stroke

Mouse

Transient- MCAO
(120 min occlusion time)

MBL−/−
MBL−/− + MBL

Lectin
pathway

(1) MBL deficiency resulted in significantly reduced infarct volume, neurological impairment and C3
deposition. (2) Reconstitution of MBL in MBL−/− mice resulted in a larger infarct volume. Outcomes
were measured at 48 h

(78)

Ischemic stroke

Rat

Transient- MCAO
(120 min occlusion time)

WT + sCR1

Classical
pathway

sCR1 significantly reduced infarct volume, myeloperoxidase activity, and C3d deposition 24 h after
reperfusion

(79)

Ischemic stroke

Mouse

Neonatal hypoxia

C1q−/−

Classical
pathway

(1) C1q−/− mice had significantly lower infarct volume, improved neurological score, lower C3
deposition, and less leukocyte activation at 24 h. (2) C1q−/− mice also had lower cerebral atrophy
and better performance on water maze up to 8 weeks after hypoxia-ischemia

(80)

Ischemic stroke

Rat

Photochemical cortical
vein occlusion

WT + C1 Inhibitor

Classical
pathway

C1 Inhibitor significantly reduced infarct volume 2 h after occlusion

(32)

Ischemic stroke

Mouse

Permanent MCAO

C3−/−
WT + C3aRA

All pathways

Both C3−/− and C3aRA reduced ischemia-induced neurogenesis in the sub-ventricular zone, infarct
area, and penumbra at 7 days after injury despite no significant change in infarct volume

(81)

Ischemic stroke

Rat

MCAO

None

All pathways

CD11b, C1q, and C3c increased significantly in ischemic brain and remained elevated till 7 days

(82)

Ischemic stroke

Mouse

Transient- MCAO (90 min
occlusion time)

MBL−/−

Lectin
pathway

(1) MBL−/− significantly reduced infarct volume and neurological deficit on days 1 and 7 after
reperfusion. (2) MBL−/− reduces fibrinogen accumulation in brain vasculature

WT

Ischemic stroke

Mouse

Transient- MCAO (60 min
occlusion time)

MBL−/−
WT

Lectin
pathway

(1) MBL-a/c were found to accumulate in the brain after stroke peaking at 24 h. (2) MBL−/−
improved acute (day 1) but not subacute (day 7) measures of infarct volume and neurological
deficit

(84)

Ischemic stroke

Mouse

Permanent and transientMCAO (30 min occlusion
time)

MBL−/−
WT
WT + polymannosylated
dendrimers

Lectin
pathway

(1) MBL is deposited on ischemic vessels with a peak at 24 h and is associated with increased C3
deposition. (2) MBL−/− mice had significantly lower infarct volume compared to WT after permanent
and transient MCAO. (3) Polymannosylated dendrimers (specifically Polyman2) given up to 30 h
after reperfusion significantly reduced C3 deposition, infarct volume, and neurological deficit in WT
mice at 48 h only in transient MCAO

(84)

Ischemic stroke

Rat

Three-vessel occlusion

WT

Lectin
pathway

(1) Anti-MBL-A antibody given up to 18 h after ischemia reduced neurological deficit and infarct
volume at 48 h. (2) The protective effect of anti-MBL-A administration was maintained up to
28 days after ischemia

WT + anti-MBL-A
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complement hemolytic activity, but failed to improve neurological
outcome; in fact, treatment increased infarct volume in baboons.
One possible explanation for this outcome is that sCR1-sLex has
multivalent selectin-targeting sites and may promote homotypic
platelet–platelet aggregation, and potentially thrombosis.
Another strategy used to target complement inhibition to an
anatomical site is to link a complement inhibitor to a recombinant
portion of complement receptor type 2 (CR2). Ligands for CR2
are C3 activation products that become covalently attached
at sites of complement activation (57). Complement receptor
1-related gene/protein-y (Crry) is a rodent structural and functional analog of CR1, and a CR2-Crry construct administered
90 min after ischemia in a murine MCAO model was shown
to improve survival, reduce infarct volume, reduce P-selectin
expression and neutrophil recruitment, and improve neurological outcome. Acute outcomes after a single injection of CR2-Crry
were comparable to those in C3-deficient mice (57). It has also
been shown that targeted complement inhibition with CR2-Crry
does not impair host susceptibility to infection, unlike systemic
inhibition of C3 deficiency, a potentially important consideration
for stroke patients who are at increased risk of infection (57).
The sCR1 and Crry inhibitors described above are pan complement inhibitors. Interventional studies in experimental models
of stroke have also been performed with C1-inhibitor (C1-inh)
that inhibits only the classical and lectin pathways. In various
ischemic stroke models, C1-inh has been shown to decrease
infarct volume (56, 62, 64, 70, 80), reduce focal and general deficits (62–64), inhibit leukocyte infiltration and myeloperoxidase
activity (56, 63, 64), and diminish neuronal apoptosis (63, 64)
(summarized in Table 2). Taken together with the data reported
above that C1q deficiency is not protective in murine models of
ischemic stroke, these data suggest a role for the lectin pathway
in promoting cerebral IRI. Of note, however, all of the studies
with C1-inh evaluated acute outcome after stroke, and it is possible that C1q-mediated uptake of apoptotic cells, an important
anti-inflammatory and reparatory mechanism, may play a role in
outcome in the subacute phase after stroke.
Further investigation has indeed demonstrated an important
role for the lectin pathway in murine models of stroke. MBL deficiency resulted in significantly reduced infarct volumes, neurological impairment, and C3 deposition, whereas reconstitution of
MBL-deficient mice with MBL resulted in larger infarct volumes
(77). Two additional studies have also since demonstrated that
MBL deficiency is protective against ischemic stroke (82, 84), and
it has also been shown that an inhibitor of the lectin pathway,
Polyman2, is protective when given up to 24 h after ischemia
in mice (84). The same study demonstrated that an anti-MBL
antibody is also protective in a rat model of stroke when given
up to 18 h after ischemia, and as assessed 28 days after stroke.
Thus, lectin pathway inhibition appears to be a therapeutic target
with a wide therapeutic window. It should be noted, nevertheless,
that Morrison et al. [(74) p. 52] found no significant difference
in infarct volume, brain edema, or complement deposition
between wild-type and MBL-deficient mice, and that Ducruet
et al. (83) found that acute-phase protection in MBL-deficient
mice was not sustained in the subacute phase. With regard to the
different subacute outcomes in lectin pathway deficient vs. lectin
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pathway inhibited mice, an explanation could be that while acute
complement activation is injurious, it also plays a role in repair
and regenerative mechanisms in the subacute phase. Unlike
deficiency, acute temporary lectin pathway inhibition would have
minimal impact on the lectin pathway in the subacute phase.
The alternative complement pathway can be spontaneously
activated, but it also serves as an amplification loop for the classical or lectin pathways. Whichever way complement is activated, it
has been estimated that 80% of complement activation products
can be the result of alternative pathway amplification (92). This is
likely the reason that although the classical and lectin pathways
can variously play essential roles in autoimmune, inflammatory,
and ischemic disease models, the alternative pathway is nearly
always required for full in vivo expression of injury (93, 94). And
cerebral IRI is no exception, since although the studies reported
above indicate a key role for the lectin pathway in ischemic
stroke, mice deficient in factor B (alternative pathway protein)
or treated with CR2-fH (targeted alternative pathway inhibitor)
were protected to a similar extent as C1q/MBL-deficient mice
in terms of several injury and neurological outcome measures
(72). Together these data indicate that the alternative pathway is
not alone sufficient to initiate complement activation, but that it
acts to propagate cerebral injury via amplification of the cascade.
Of note, a single CR2-fH treatment administered 90 min post
ischemia resulted in significantly reduced astrocyte reactivity,
cellular apoptosis and infarct volume for up to 7 days after reperfusion (72). In unpublished work, we have shown that unlike
CR2-fH, CR2-Crry does not provide sustained protection into
the subacute phase after stroke. This may reflect an advantage
of not blocking all complement pathways in order to maintain
some level of complement activation that may contribute to
homeostatic or repair processes.
With regard to the terminal complement pathway, data indicate
that the MAC is an important mediator of IRI in several organs
and tissues, including spinal cord injury (95) and traumatic brain
injury (96). In the case of cerebral IRI, however, the role of the
MAC is less clear. Mice deficient in C6, a component of the MAC,
are not protected from cerebral injury after 60 min MCAO and
24 h reperfusion, indicating that the MAC does not play a role
in cerebral IRI (72). In agreement with this conclusion, mice
deficient in CD59, a membrane-bound inhibitor of the MAC,
do not display exacerbated cerebral injury in the same model
(72). However, CD59-deficient mice show worse outcomes in the
MCAO model with shorter ischemic times (30 min as opposed
to 60 min), and thus the terminal pathway may contribute to cerebral IRI under conditions of less severe injury or ischemia (76).
Studies on the anaphylatoxins, C3a and C5a, have indicated
important roles for these peptides in cerebral IRI. In a transient
MCAO model, C3-deficient mice and wild-type mice treated
with a C3a receptor antagonist (C3aRA) showed significant
improvements in infarct volume and neurological outcomes, with
less granulocyte infiltration. Furthermore, the effect was reversed
when C3-deficient mice were reconstituted with C3 (60). A similar effect of C3aRA was shown in a transient MCAO model (66),
but not in a model with permanent occlusion (73). The different
effects of C3aRA in the two models may be related to inhibition
of C3a-dependent activation of blood-derived immune cells
10
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following reperfusion. C5aR1-deficient mice are also protected
against cerebral IRI following transient MCAO (44), but pretreatment of wild-type mice with C5aRA did not consistently improve
neurological outcome or infarct volume (42, 65). Interestingly,
C5aRA was also found to improve outcome in animal models of
hemorrhagic stroke, either alone or in combination with C3aRA
(53, 67, 69). These studies on the role of C3a and C5a in stroke
pathogenesis were performed by analyzing acute outcomes,
and it remains unclear what effect interfering with C3a- and
C5a-mediated signaling would have on subacute and chronic
outcomes. A concern with inhibiting C3a and C5a signaling,
especially at later time points after stroke, is the effect on neurogenesis and cognitive performance, since both anaphylatoxins
have implicated roles in basal and stress-induced neurogenesis
(32–34). In this regard, a study using C3aRA treatment after
MCAO indicated that the effect of C3a inhibition on neurogenesis is dose dependent. High-dose treatment with C3aRA (twice
daily for 10 days) reduced ischemia-induced neurogenesis in the
sub-ventricular zone, infarct area, and penumbra at 7 days after
permanent MCAO (32). However, low dose C3aRA treatment
increased neurogenesis in a dose-dependent fashion on day 7 in
a transient MCAO model with 30 min ischemia (73). This may
indicate that a titrated reduction of C3a-dependent signaling may
limit the pro-inflammatory effects of C3a (especially in models
that include reperfusion), while at the same time maintain the
homeostatic effects of C3a on neurogenesis.
So what is the complement-activating event after stroke?
Seminal studies by Williams et al. (97) and Zhang et al. (98, 99)
demonstrated that following intestinal ischemia and reperfusion,
complement is activated by natural self-reactive IgM antibodies

that recognize post-ischemic neoepitopes. By screening IgMproducing hybridomas, an IgM monoclonal antibody was isolated that could restore pathogenic injury in otherwise protected
antibody-deficient (Rag1−/−) mice. The intestinal target of this
mAb was identified as non-muscle myosin (98), and antibodies
to this post-ischemic neoepitope have additionally been shown to
play a role in hind-limb (100) and myocardial IRI (101). Although
the early studies attributed IgM-mediated activation of the classical pathway as an initiating event in IRI, more recent studies
have demonstrated that IRI is driven by IgM-mediated activation
of the lectin pathway, at least in the organ systems that have
been investigated (99, 102, 103). The animal studies described
above, and the human studies described below, indicate that the
lectin pathway also initiates cerebral IRI, and recent studies have
demonstrated that pathogenic natural IgM also plays a role in
propagating injury in murine ischemic stroke (71) (Figure 3).
As with intestinal IRI, Rag1-deficient mice are protected from
cerebral IRI, and two IgM monoclonal antibodies were identified that reconstituted cerebral IRI in Rag1-deficient mice; these
monoclonal antibodies recognized annexin IV and a subset of
phospholipids, and thus identified danger-associated molecular
determinants expressed after stroke in mice (71). Post-ischemic
blockade of annexin IV or phospholipid neoepitopes thus represents a potential therapeutic strategy for inhibiting complement
activation and reducing cerebral IRI. The same two post-ischemic
neoepitopes are also expressed in the intestine (104) and heart
[(57), Circulation, in press] after ischemia and reperfusion,
indicating that similar pathophysiologically important epitopes
recognized by IgM natural antibodies are expressed in different
organs and tissues. Furthermore, it has been shown that human

FIGURE 3 | Triggers of complement activation after cerebral ischemiareperfusion injury. Ischemic insult induces expression of neoepitopes or
danger-associated molecular patterns (DAMPs) on the surface of stressed
endothelial cells. The exposed DAMPs are recognized by circulating natural
self-reactive antibodies, principally IgM, which triggers complement activation.
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Although IgM binds C1q, it appears to be the binding of MBL and activation of
the lectin pathway that drives ischemia and reperfusion injury in the organs
systems examined, including the brain. Complement can be also activated
through direct binding of C1q to apoptotic cells, as well as through C-reactive
protein-induced complement activation.
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endothelial cells (HUVEC) express these two neoepitopes after
exposure to hypoxia (71).

as removal of debris, and when anaphylatoxins may contribute
to homeostatic pro-survival and neuro-regenerative effects. It
will be important to investigate how manipulation of the complement system impacts subacute and chronic outcomes, as well as
to evaluate areas away from the ischemic core. Investigation of
chronic outcomes may reveal a role for complement in maintaining neuronal survival after acute damage has been resolved, and
possible mechanisms may include stimulation of neuronal growth
factor production by astrocytes and microglia (35, 36), or reduction of glutamate-induced excitotoxicity (37–40). Stroke and brain
injury are associated with a window of synaptic plasticity after
injury that contributes to neurological recovery (88, 90). While
various mechanisms have been implicated in this process, a role
for complement has not been investigated. Based on the essential
role of complement in synaptic pruning during CNS development, complement may also play a role in synaptic pruning and
hippocampal plasticity after stroke, and may thus contribute to
improved neurological outcome and facilitate rehabilitation.
Going forward, the design of experimental models to assess
longer endpoints and multiple outcome measures after stroke
may reveal a more diverse role for complement in ischemic injury
and rescue. Future studies should also investigate the role of different complement components in early and delayed pathophysiological events. One area of investigation that has received little
attention is the role of complement opsonins in early neuronal
and synaptic loss after stroke, as well as the role of these opsonins
in the resolution of inflammation and synaptic re-wiring that
can occur later. Future studies should also address the interplay
between complement opsonins and immune cells bearing
receptors for these opsonins, especially infiltrating and resident
macrophages/microglia; these opsonins may also play a role in
driving macrophage polarization toward an anti-inflammatory
and pro-regenerative phenotype. We also have an incomplete
understanding of the role of the anaphylatoxins in stroke. They
are implicated in recruiting and activating immune cells acutely,
as well as stimulating neuronal genesis and migration in delayed
phases after stroke. It is also not clear whether C3a and C5a have
redundant, overlapping, or possibly divergent effects. Tools to
address these questions are available in the form of genetically
deficient mice and inhibitors that block the generation of specific
complement activation products or that antagonize complement
receptors, and it will be important for future studies to better
evaluate long-term effects and outcomes after stroke.

Studies in Human Patients

There are no reported clinical trials on the use of complement
inhibition in stroke, a direct consequence of the aforementioned
conflicting pre-clinical data. Before an intervention can enter
a clinical trial, stringent criteria recommended by the stroke
therapy academic industry roundtable (STAIR) must be met.
In brief, there should be consistent pre-clinical data in different
animal species and in animal cohorts that represent the human
stroke predisposed population. Such populations include both
sexes, adult and elderly age groups, and patients with comorbidities such as hypertension and diabetes (105). Thus, studies on the
role of complement in human stroke are correlational.
Studies on gene polymorphisms at complement gene loci,
associated polymorphisms at the C5 and factor H gene loci with
increased incidence of cerebrovascular accidents (106, 107).
Among 16 single nucleotide polymorphisms (SNPs) at the C3
gene locus, two SNPs (rs2277984 and rs3745565) were associated
with ischemic stroke (108). MBL genotype is also associated with
stroke severity. In two cohorts of stroke patients, MBL-sufficient
phenotypes were associated with larger infarct and less favorable
outcome compared to MBL-deficient phenotypes (77, 109).
Prospective studies on men with advanced atherosclerosis, higher
levels of C4 and C5 are associated with the incidence of stroke
(110). Similarly, a prospective study of 5850 healthy men showed
that C4 and C3 levels correlated with other cardiovascular risk
factors, and that very high C4 levels may predict the incidence
of stroke (111). C4 was also shown to be a stroke predictor in
men with known or suspected coronary artery disease (112).
Compared to healthy volunteers, stroke patients were found to
have higher plasma levels of C3a, C3, C4, C5, factor B, and the
terminal complement complex (113–118). Serum levels of C3,
C3c, and C4 were also associated with increased stroke severity in
cardio-embolic stroke patients (118, 119). Despite these human
studies that report alterations in serum complement levels in
stroke patients and the association with outcome, the studies
remain correlative and cannot demonstrate a definitive role for
complement in the pathogenesis of stroke. Table 3 summarizes
studies investigating complement system changes in patients with
ischemic or hemorrhagic stroke.

Future Perspectives on the Dual role of
Complements in Brain I/R

Clinical and Translational Perspective

The predominant focus of studies on complement and stroke has
been on the role of complement in perpetuating the inflammatory
cascade and contributing to neuronal death. By comparison, very
few studies have investigated the putative protective role that
complement may play in ischemic rescue and ischemia-induced
neurogenesis. The great majority of reports investigate acutephase outcomes where complement blockade prevents activation
of pro-inflammatory mechanisms. However, as indicated by a few
studies, the same favorable outcomes may not occur in the subacute and chronic phases after stroke, when complement opsonins
may be important for mediating anti-inflammatory events such

As mentioned in Section “Studies in Human Patients,” polymorphism in complement genes is associated with ischemic stroke,
and that acute stroke patients have higher serum levels of complement proteins compared to controls (Table 3). In addition,
postmortem studies have identified both complement and IgM
deposition in the human brain after stroke (125). This suggests
that complement activation and deposition occurs in the human
brain similarly to that in experimental models. Thus, given the
correlation between complement activity and stroke outcome in
human patients, the use of complement inhibition holds promise
as a potential therapeutic intervention. Optimally, a complement
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TABLE 3 | Summary of studies performed in human patients investigating the role of complement in cerebral I/R.
Study

Patient condition

Controls

Assay

Pathway

Relevant findings

(118)

Cardio-embolic and small
vessel disease stroke
(n = 79 each)

Matched control
groups (n = 40 each)

ELISA for C3 and C3a levels

All pathways

(1) C3 and C3a were elevated acutely in both
groups, and only C3 remained elevated at
3 months in both groups.(2) Phasic increase of
C3 was associated with unfavorable outcome
only in cardio-embolic patients

(120)

Coronary vessel disease,
MI, and ischemic stroke (n
~55 each)

Matched controls

Immunofluorometric assay of
MASP-1,2,3,4

Lectin pathway

(1) MASP-1 and MASP-2 levels were low in
stroke patients. (2) MASP-3,4 levels were not
different from controls

(107)

Carotid atherosclerosis
(n = 1065)

None

Polymorphism in C5 gene

All pathways

Polymorphism of C5 gene was associated with
increased plasma C5a levels and increased
incidence of MACE in men

(121)

Fatal ischemic brain
infarction (n = 10)

None

Immunohistochemistry of C9
deposition

Common
terminal
pathway

Infarct areas associated with increased C9
deposition and neutrophil infiltration

(113)

Acute stroke (n = 11)

Healthy volunteers
(n = 9)

Serum levels of complement and Common
inflammatory components
terminal
pathway

(1) Terminal complement complex and CRP
levels increased at 3–12 days after stroke
compared to controls. (2) No significant
change in soluble adhesion molecules and
cytokines

(122)

Cerebrovascular disease
(n = 292)

Healthy volunteers
(n = 198)

Genotype of C4B alleles.

Classical
pathway

There was significantly lower incidence of allotype C4B1Q0 in patients with cerebrovascular
disease compared to control

(119)

Cardio-embolic,
thromboembolic, and
lacunar stroke patients
(n = 194)

NA

C3c and C4

Classical and
alternative
pathways

(1) Serum concentration of C3c and C4 was
significantly reduced in cardio-embolic stroke
compared to atherothrombotic and lacunar
strokes. (2) Serum concentration reflects the
stroke severity only in cardio-embolic stroke

(110)

Advanced atherosclerosis
(n = 173)

None

C5a

All pathways

Complement activation with increased C5a
levels is associated with higher risk of MACE.

(123)

Ischemic stroke (n = 80)

None

Platelet C4d levels

Classical
pathway

Platelet C4d is associated with severe acute
ischemic stroke.

(124)

Ischemic stroke (n = 26)

Severe carotid
atherosclerosis
(n = 26)

sC5b-9 and C4d levels

Classical and
common
terminal
pathway

(1) sC5b-9 and C4d were higher in stroke
patients. (2) Levels of sC5b-9 were associated
with stroke severity and functional disability

(125)

Brains of stroke patients
(n = 10)

Control brains (n = 10)

Postmortem complement levels.

Classical and
common
terminal
pathway

Ischemic areas showed C1q, C4d, and C3c
deposition as well as marked reduction in
CD59 compared to normal tissue

(108)

Stroke patients (n = 844)

Healthy controls
(n = 668)

Assay of 16 SNPs at C3 locus.

All pathways

Two SNPs at the C3 gene locus (rs2277984
and rs3745565) were associated with ischemic
stroke

(116)

Stroke patients (n = 179)

Healthy controls
(n = 156)

C3 and C4 plasma levels and
complement hemolytic activity.

All pathways

Complement levels of C3 and C4 were
elevated in stroke patients and associated with
a worse neurological outcome.

(59, 60, Stroke patients (n = 16)
115)

Healthy controls
(n = 16)

C3a, C5a, and sC5b-9 levels in
plasma

All pathways

(1) C3a was significantly elevated in stroke
patients compared to controls till day 28. (2)
C5a levels were elevated at 7–14 days. (3)
sC5b-9 levels were significantly depressed in
stroke patients till day 2.

(112)

None

C4 plasma levels

Classical
pathway

Serum component C4 is predictor of stroke
with known or suspected heart disease.

Men with known or
suspected coronary artery
disease (n = 389)

(Continued)
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TABLE 3 | Continued
Study

Patient condition

Controls

Assay

Pathway

Relevant findings

(111)

Initially healthy men
(n = 5850)

None

C3 and C4 plasma levels.

Classical and
common
terminal
pathway

(1) Serum C3 and C4 levels correlated with
other cardiovascular risk factors. (2) Very
high C4 levels may be associated with stroke
incidence

(126)

First degree relatives to
South Asian stroke patients
(n = 143)

South Asian (n = 121)
and white (n = 141)
controls

C3, factor B, and CRP plasma
levels

Alternative
pathway

(1) No significant difference in C3, CRP, and
factor B levels between South Asian first
degree relatives and controls. (2) Only C3 and
CRP levels were higher in South Asian groups
compared to controls

(106)

Caucasians who developed
a ischemic stroke (n = 235)

Controls (n = 235)

Complement factor H Y402H
gene polymorphism

Alternative
pathway

No association of Y402H polymorphism with
risk of ischemic stroke

(117)

Cryptogenic stroke (n = 79)
and large vessel disease
stroke (n = 73)

Controls (n = 79)

Plasma C3 and C3a levels

All pathways

(1) C3 levels were elevated in stroke patients
compared to controls. (2) Higher C3a levels
were associated with stroke. (3) Plasma
levels of C3 were associated with unfavorable
outcome in large vessel disease patients at
3-month and 2-year interval.

(109)

Ischemic stroke (n = 353)

None

MBL plasma levels.

Lectin pathway

MBL deficiency is associated with smaller
cerebral infarcts and favorable outcome in
patients receiving conservative treatment.

(77)

Ischemic Stroke (n = 135)
and hemorrhagic stroke
(n = 26)

None

MBL genotype and plasma
levels.

Lectin pathway

Unfavorable outcome was associated with
MBL-sufficient genotype and MBL-circulating
level

(127)

Patients with first ischemic
stroke (n = 1451)

None

C3 and C4 plasma levels.

Terminal
Pathway

C3 (not C4) levels of stroke patients on
admission was independently associated with
prognosis in male patients 3 months after the
acute event

(128)

Patients with first ischemic
stroke (n = 220)

Healthy controls
(n = 100)

MBL plasma levels.

Lectin Pathway

MBL was an independent prognostic marker
of functional outcome and death 90 days after
stroke

(129)

Infants with hypoxicischemic encephalitis
(n = 16)

Healthy controls (n = 7) C9 and MAC levels in CSF.

Terminal
pathway

(1) Infants with hypoxic-ischemic encephalitis
had significantly higher MAC levels and
significantly lower C9 levels in CSF compared
to controls. (2) Postmortem staining of brain
tissue of two infants revealed C9 deposition on
morphologically apoptotic neurons.

inhibitor should effectively inhibit early pathogenic complement
activation without depleting systemic complement activity in
order to maintain the homeostatic and protective role of complement during recovery. A clear understanding of the role of
different complement activation products and their spatial and
temporal effects will be important to guide the development of
an optimal anti-complement therapeutic strategy. As a final note,
thrombolytic therapy using t-PA also results in complement

activation (130), and it is possible that complement inhibition in
the context of t-PA administration could provide a new adjuvant
therapy to t-PA.
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